This product is based on the liquid hybrid capture technology called TargetSeq® which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 16.06MB, including 5083 genes associated with hereditary disease and 181 well-reported pathogenic sites. It can detect common hereditary diseases related to SNP, InDel, CNV, SNV, SV, fusion.

This product is based on the liquid hybrid capture technology called TargetSeq® which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 301.61K, which contains 91 genes associated with hereditary deafness.

This product is based on the liquid hybrid capture technology called TargetSeq® which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 306K and contains 195 genes associated with genetic disease.

This product is based on the liquid hybrid capture technology called TargetSeq® which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 342.9K, which contains 183 genes associated with hereditary tumors.

This product is based on the liquid hybrid capture technology called TargetSeq® which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 79.195K, which contains 8 genes associated with Lung cancer.

This product is based on the multiplex PCR target enrichment method called MultipSeqTM which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. The target region is 17.24KB, which contained the full exon region of BRCA1 and BRCA2 gene, and could detect the SNP and InDel.

This product is based on the multiplex PCR target enrichment method called MultipSeqTM which developed by iGeneTech® independently. It's adapted to the current mainstream high-throughput sequencing platform. Its contains 50 tumor-related genes in all exon regions, and could detect the SNP and InDel.